NCT01944735View on ClinicalTrials.gov

Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Cystic Fibrosis
Interventions
DRUG

CTX-4430

Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.

DRUG

Placebo

Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15

Trial Locations (4)

M23 9QZ

The Medicinces Evaluation Unit, Wythenshawe

BT9 6AD

Celerion, Belfast

G31 2ER

Glasgow Clinical Research Facility, Glasgow

SW3 6NP

Royal Brompton Hospital, London

Sponsors

Lead Sponsor

Celtaxsys, Inc.

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Celtaxsys, Inc.

OTHER

NCT01944735 - Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients | Biotech Hunter | Biotech Hunter